Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$14.19 USD
+0.22 (1.57%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $14.18 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.19 USD
+0.22 (1.57%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $14.18 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Zacks News
Here's Why Pacira (PCRX) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Pacira (PCRX) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Pacira (PCRX) Rides High in YTD Period on Robust Exparel Sales
by Zacks Equity Research
Pacira's (PCRX) flagship product, Exparel, has been performing well since its launch. The company's efforts to expand the drug's label also holds promise.
Pacira's (PCRX) Q4 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira's (PCRX) earnings surpass estimates in the fourth quarter of 2021 while revenues are slightly above estimates.
Pacira (PCRX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of 16.87% and 0.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Pacira (PCRX) Q4 Earnings Expected to Decline
by Zacks Equity Research
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
InMed Pharmaceuticals Inc. (INM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
InMed Pharmaceuticals Inc. (INM) delivered earnings and revenue surprises of -29.17% and 6%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Community Health (CYH) Unit Declares Pricing of Senior Notes
by Zacks Equity Research
Community Health's (CYH) wholly-owned arm exhibits monetary discretion by pricing senior notes to procure funds.
The Zacks Analyst Blog Highlights: Pacira BioSciences, D.R. Horton ArcBest, Axis Capital Holdings and CF Industries
by Zacks Equity Research
Pacira BioSciences, D.R. Horton ArcBest, Axis Capital Holdings and CF Industries are highlighted in this Analyst Blog Article.
5 Reasons to Bet On These 5 Buy Ranked Stocks
by Sejuti Banerjea
PCRX, DHI, ARCB, AXS and CF balance value and growth and are therefore worth picking up.
Here's Why Seasoned Investors are Retaining Mednax (MD)
by Zacks Equity Research
Banking on its strategic measures and a streamlined business, Mednax (MD) holds potential to reap benefits for investors.
BioCryst (BCRX) Stock Up on Q4 Orladeyo Preliminary Sales
by Zacks Equity Research
BioCryst's (BCRX) sole marketable drug, Orladeyo reports preliminary sales for the fourth quarter. The company also provides its revenue guidance for 2022.
Why Seasoned Investors are Retaining Community Health (CYH)
by Zacks Equity Research
Community Health Systems (CYH) is focused on making strategic acquisitions to boost its business through inorganic growth.
Here's Why You Should Retain Centene (CNC) in Your Portfolio
by Zacks Equity Research
Centene (CNC) is well poised for growth on the back of improving revenues, continuous expansion plans for the MA business and sufficient cash-generating abilities.
Amgen (AMGN) Inks Multi-Target Deal to Make Protein Therapeutics
by Zacks Equity Research
Amgen (AMGN) signs a collaboration agreement with Generate Biomedicines to develop protein therapeutics across several therapeutic areas and multiple modalities.
Pacira (PCRX) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Pacira (PCRX) could produce exceptional returns because of its solid growth attributes.
Pacira (PCRX) Down 4.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacira's (PCRX) Q3 Earnings Beat Estimates, Revenues Miss Mark
by Zacks Equity Research
Pacira's (PCRX) earnings beat estimates in the third quarter of 2021 while revenues miss the same. Its flagship product Exparel's sales rise year over year.
Pacira (PCRX) Beats Q3 Earnings Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of 9.09% and -2.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Flexion (FLXN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Flexion's (FLXN) third-quarter earnings call, investor focus will be on its updates on earnings and revenues and the upcoming merger with Pacira whereby the latter will acquire the former.
Pacira (PCRX) Gets Notification of ANDA for Exparel, Stock Down
by Zacks Equity Research
Pacira (PCRX) receives a Paragraph IV Certification notice letter notifying that eVenus has submitted an ANDA for marketing a generic version of Exparel in the United States.
Pacira (PCRX) Down 1.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacira's (PCRX) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira's (PCRX) earnings and revenues in the second quarter of 2021 surpass estimates. Exparel sales surge year over year.
Pacira (PCRX) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of 1.32% and -0.01%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?